TransUnion’s Return On Invested Capital Overview

According to Benzinga Pro, during Q2, TransUnion (NYSE:TRU) earned $99.70 million, a 92.1% increase from the preceding quarter. TransUnion also posted a total of $948.30 million in sales, a 2.93% increase since Q1.

According to Benzinga Pro, during Q2, TransUnion (NYSE:TRU) earned $99.70 million, a 92.1% increase from the preceding quarter. TransUnion also posted a total of $948.30 million in sales, a 2.93% increase since Q1. TransUnion earned $51.90 million, and sales totaled $921.30 million in Q1.

What Is Return On Invested Capital?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company’s ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q2, TransUnion posted an ROIC of 1.35%.

Keep in mind, while ROIC is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company’s ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q2, TransUnion posted an ROIC of 1.35%.

Keep in mind, while ROIC is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

For TransUnion, the positive return on invested capital ratio of 1.35% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

TransUnion reported Q2 earnings per share at $0.98/share, which beat analyst predictions of $0.97/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Scilex Holding Company Releases Preliminary Unaudited Financial Results For Gross And Net Sales For The Year Ended December 31, 2023; Total Product Gross Sales Were In The Range Of $150M-$155M; Total Product Net Sales Were In The Range Of $46.5M-$52.5M

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute

SCLX